Exclusion
LQT08-hiPSC
Exclude from clean allogeneic source-line shortlist.
Disease-model or disease-related mutation evidence is present.
StatusExclusion
Exportable report preview with candidate lines, exclusion flags, evidence matrix, HLA readiness, next evidence, source index, and caveats.
Executive Summary
McClintock indexes Korean iPSC source-line evidence, separates green QC from exclusion flags, and identifies the next evidence needed before HLA or CMC readiness claims.
Generated Jul 3, 2026, 8:03 AM UTC
LQT08-hiPSC
Disease-model line with disease-related mutation, not a clean allogeneic source-line candidate.
PB01-EiPS21-EGFP04
Reporter / EGFP knock-in research line, not a clean allogeneic source-line candidate.
| Evidence Category | KSCBi005-ACMC-hiPSC-003 | KSCBi018-ACMC-hiPSC-011 | KSCBi019-ACMC-hiPSC-009 | KSCBi020-ACMC-hiPSC-022 | KSCBi021-ACMC-hiPSC-005 | KSCBi027-AKNIH01 | KSCBi028-ACMC-hiPSC-006 | LQT08-hiPSC01_P_CMC-SiPS1 | PB01-EiPS21-EGFP04National Stem Cell Bank of Korea |
|---|---|---|---|---|---|---|---|---|---|
| Identity basic qc | |||||||||
| Cell viability | |||||||||
| STR authentication | |||||||||
| Mycoplasma PCRBlocker | |||||||||
| Microbial contaminationBlocker | |||||||||
| Viral contaminationBlocker | |||||||||
| Cell attachment / morphology | |||||||||
| Karyotype G-bandingBlocker | |||||||||
| Abnormal karyotype flagBlocker | |||||||||
| Pluripotency differentiation | |||||||||
| Pluripotency AP staining | |||||||||
| Pluripotency ICC | |||||||||
| Pluripotency qRT-PCR | |||||||||
| Differentiation EB formation | |||||||||
| Differentiation qRT-PCR | |||||||||
| Culture reprogramming | |||||||||
| Culture matrix | |||||||||
| Culture media | |||||||||
| Dissociation method | |||||||||
| Freezing media | |||||||||
| Source cell type | |||||||||
| Reprogramming method | |||||||||
| Feeder-free | |||||||||
| Xeno-free | |||||||||
| Hla population fit | |||||||||
| HLA typingBlocker | |||||||||
| HLA homozygous flag | |||||||||
| HLA population-fit score | |||||||||
| Genomics omics | |||||||||
| SNP / CNV | |||||||||
| WES or indel | |||||||||
| RNA-seq | |||||||||
| Methyl-seq | |||||||||
| STR profile detail | |||||||||
| Gmp regulatory commercial | |||||||||
| GMP documentationBlocker | |||||||||
| Formal CoABlocker | |||||||||
| Consent / commercial-use rightsBlocker | |||||||||
| Donor provenanceBlocker | |||||||||
| Distribution vial availability | |||||||||
| Clinical-grade supply status | |||||||||
| Exclusion flags | |||||||||
| Genetic modification statusBlocker | |||||||||
| Reporter line flagBlocker | |||||||||
| Disease-model flagBlocker | |||||||||
| Disease-related mutationBlocker | |||||||||
| Knockout / knock-in flagBlocker | |||||||||
Allele completeness: 0%
Allele-level HLA typing is missing, so population fit cannot be computed.
Allele completeness: 0%
Allele-level HLA typing is missing, so population fit cannot be computed.
Allele completeness: 0%
Allele-level HLA typing is missing, so population fit cannot be computed.
Allele completeness: 0%
Allele-level HLA typing is missing, so population fit cannot be computed.
Allele completeness: 0%
Allele-level HLA typing is missing, so population fit cannot be computed.
Allele completeness: 0%
Allele-level HLA typing is missing, so population fit cannot be computed.
Exclusion
Exclude from clean allogeneic source-line shortlist.
Disease-model or disease-related mutation evidence is present.
Exclusion
Exclude from clean allogeneic source-line shortlist.
Genetic modification is present or reported for this line.
Next evidence
Obtain high-resolution HLA-A/B/C/DRB1/DQB1/DPB1 typing before population-fit claim.
Population-fit readiness cannot be computed without allele-level HLA typing.
Rights review
Verify donor consent and commercial-use rights.
Commercial-use rights are a blocker for source-line selection.
Next evidence
Obtain high-resolution HLA-A/B/C/DRB1/DQB1/DPB1 typing before population-fit claim.
Population-fit readiness cannot be computed without allele-level HLA typing.
Rights review
Verify donor consent and commercial-use rights.
Commercial-use rights are a blocker for source-line selection.
Next evidence
Obtain high-resolution HLA-A/B/C/DRB1/DQB1/DPB1 typing before population-fit claim.
Population-fit readiness cannot be computed without allele-level HLA typing.
Rights review
Verify donor consent and commercial-use rights.
Commercial-use rights are a blocker for source-line selection.
Next evidence
Obtain high-resolution HLA-A/B/C/DRB1/DQB1/DPB1 typing before population-fit claim.
Population-fit readiness cannot be computed without allele-level HLA typing.
Rights review
Verify donor consent and commercial-use rights.
Commercial-use rights are a blocker for source-line selection.
Next evidence
Obtain high-resolution HLA-A/B/C/DRB1/DQB1/DPB1 typing before population-fit claim.
Population-fit readiness cannot be computed without allele-level HLA typing.
Rights review
Verify donor consent and commercial-use rights.
Commercial-use rights are a blocker for source-line selection.
Next evidence
Obtain high-resolution HLA-A/B/C/DRB1/DQB1/DPB1 typing before population-fit claim.
Population-fit readiness cannot be computed without allele-level HLA typing.
Rights review
Verify donor consent and commercial-use rights.
Commercial-use rights are a blocker for source-line selection.
Next evidence
Obtain high-resolution HLA-A/B/C/DRB1/DQB1/DPB1 typing before population-fit claim.
Population-fit readiness cannot be computed without allele-level HLA typing.
Rights review
Verify donor consent and commercial-use rights.
Commercial-use rights are a blocker for source-line selection.
Next evidence
Obtain high-resolution HLA-A/B/C/DRB1/DQB1/DPB1 typing before population-fit claim.
Population-fit readiness cannot be computed without allele-level HLA typing.
Rights review
Verify donor consent and commercial-use rights.
Commercial-use rights are a blocker for source-line selection.
Next evidence
Obtain high-resolution HLA-A/B/C/DRB1/DQB1/DPB1 typing before population-fit claim.
Population-fit readiness cannot be computed without allele-level HLA typing.
Rights review
Verify donor consent and commercial-use rights.
Commercial-use rights are a blocker for source-line selection.
| Priority | Line | Type | Recommendation | Rationale | Status |
|---|---|---|---|---|---|
| P0 | LQT08-hiPSC | Exclusion | Exclude from clean allogeneic source-line shortlist. | Disease-model or disease-related mutation evidence is present. | Exclusion |
| P0 | PB01-EiPS21-EGFP04 | Exclusion | Exclude from clean allogeneic source-line shortlist. | Genetic modification is present or reported for this line. | Exclusion |
| P1 | KSCBi005-A | Next evidence | Obtain high-resolution HLA-A/B/C/DRB1/DQB1/DPB1 typing before population-fit claim. | Population-fit readiness cannot be computed without allele-level HLA typing. | Open |
| P1 | KSCBi005-A | Rights review | Verify donor consent and commercial-use rights. | Commercial-use rights are a blocker for source-line selection. | Open |
| P1 | KSCBi018-A | Next evidence | Obtain high-resolution HLA-A/B/C/DRB1/DQB1/DPB1 typing before population-fit claim. | Population-fit readiness cannot be computed without allele-level HLA typing. | Open |
| P1 | KSCBi018-A | Rights review | Verify donor consent and commercial-use rights. | Commercial-use rights are a blocker for source-line selection. | Open |
| P1 | KSCBi019-A | Next evidence | Obtain high-resolution HLA-A/B/C/DRB1/DQB1/DPB1 typing before population-fit claim. | Population-fit readiness cannot be computed without allele-level HLA typing. | Open |
| P1 | KSCBi019-A | Rights review | Verify donor consent and commercial-use rights. | Commercial-use rights are a blocker for source-line selection. | Open |
| P1 | KSCBi020-A | Next evidence | Obtain high-resolution HLA-A/B/C/DRB1/DQB1/DPB1 typing before population-fit claim. | Population-fit readiness cannot be computed without allele-level HLA typing. | Open |
| P1 | KSCBi020-A | Rights review | Verify donor consent and commercial-use rights. | Commercial-use rights are a blocker for source-line selection. | Open |
| P1 | KSCBi021-A | Next evidence | Obtain high-resolution HLA-A/B/C/DRB1/DQB1/DPB1 typing before population-fit claim. | Population-fit readiness cannot be computed without allele-level HLA typing. | Open |
| P1 | KSCBi021-A | Rights review | Verify donor consent and commercial-use rights. | Commercial-use rights are a blocker for source-line selection. | Open |
| P1 | KSCBi027-A | Next evidence | Obtain high-resolution HLA-A/B/C/DRB1/DQB1/DPB1 typing before population-fit claim. | Population-fit readiness cannot be computed without allele-level HLA typing. | Open |
| P1 | KSCBi027-A | Rights review | Verify donor consent and commercial-use rights. | Commercial-use rights are a blocker for source-line selection. | Open |
| P1 | KSCBi028-A | Next evidence | Obtain high-resolution HLA-A/B/C/DRB1/DQB1/DPB1 typing before population-fit claim. | Population-fit readiness cannot be computed without allele-level HLA typing. | Open |
| P1 | KSCBi028-A | Rights review | Verify donor consent and commercial-use rights. | Commercial-use rights are a blocker for source-line selection. | Open |
| P1 | LQT08-hiPSC | Next evidence | Obtain high-resolution HLA-A/B/C/DRB1/DQB1/DPB1 typing before population-fit claim. | Population-fit readiness cannot be computed without allele-level HLA typing. | Open |
| P1 | LQT08-hiPSC | Rights review | Verify donor consent and commercial-use rights. | Commercial-use rights are a blocker for source-line selection. | Open |
| P1 | PB01-EiPS21-EGFP04 | Next evidence | Obtain high-resolution HLA-A/B/C/DRB1/DQB1/DPB1 typing before population-fit claim. | Population-fit readiness cannot be computed without allele-level HLA typing. | Open |
| P1 | PB01-EiPS21-EGFP04 | Rights review | Verify donor consent and commercial-use rights. | Commercial-use rights are a blocker for source-line selection. | Open |
| Source | Type | Owner |
|---|---|---|
| KFRM 2026 regenerative-medicine funding context | Press release | Korea Fund for Regenerative Medicine |
| NSCB characterization report example: LQT08-hiPSC | Nscb characterization report | Korea National Institute of Health |
| NSCB characterization report example: PB01-EiPS21-EGFP04 | Nscb characterization report | Korea National Institute of Health |